Prolonged diabetic ketoacidosis associated with canagliflozin.

about

Prolonged diabetic ketoacidosis associated with canagliflozin.

Item

http://www.wikidata.org/entity/Q55048274

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prolonged diabetic ketoacidosis associated with canagliflozin.

@en

Prolonged diabetic ketoacidosis associated with canagliflozin.

@nl

type

Item

label

Prolonged diabetic ketoacidosis associated with canagliflozin.

@en

Prolonged diabetic ketoacidosis associated with canagliflozin.

@nl

prefLabel

Prolonged diabetic ketoacidosis associated with canagliflozin.

@en

Prolonged diabetic ketoacidosis associated with canagliflozin.

@nl

P1476

Prolonged diabetic ketoacidosis associated with canagliflozin

@en

P2093

Gordon Sloan

http://www.w3.org/2001/XMLSchema#string

Nishant Ranjan

http://www.w3.org/2001/XMLSchema#string

Tania Kakoudaki

http://www.w3.org/2001/XMLSchema#string

P2860

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.

Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.

Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.

SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.

P31

scholarly article

P356

10.1530/EDM-17-0177

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29899991

http://www.w3.org/2001/XMLSchema#string

P932

5993060

http://www.w3.org/2001/XMLSchema#string